Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes

June 8, 2011 By Bio-Medicine.Org

LA JOLLA, Calif., and CAMBRIDGE, Mass., June 8, 2011
/PRNewswire/ — Regulus Therapeutics
Inc
., a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, and
Alnylam Pharmaceuticals, Inc. (Nasdaq:
ALNY
), a leading RNAi therapeutics company, today announced the
publication
in Nature of new pre-clinical data in mice about the
antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data
from a collaborative study performed by Regulus, Alnylam and ETH
Zurich demonstrated that antagonism of miR-103/107 with proprietary
chemically modified anti-miR oligonucleotides could promote insulin
signaling in both liver and adipose tissue.  Silencing
miR-103/107 in animal models of obesity improved glucose
homeostasis, suggesting that these microRNAs are potential targets
for the treatment of diabetes.  

Defects in insulin signaling are among the most common and
earliest defects that predispose an individual to the development
of type 2 diabetes. The new findings demonstrated that miR-103/107
are upregulated in obese mice, and silencing with anti-miRs could
improve glucose homeostasis and insulin sensitivity, while gain of
function in liver or fat caused impaired glucose homeostasis.
Direct targets of miR-103/107 identified include caveolin-1, a
critical regulator of the insulin receptor.  Upon miR-103/107
inactivation, caveolin-1 is upregulated, resulting in stabilization
of the insulin receptor, enhanced insulin signaling, decreased
adipocyte size and enhanced insulin-stimulated glucose uptake.

“microRNAs are a new class of regulatory molecules that
influence many biological functions, including metabolism. These
studies suggest t

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech